PIB is a non-specific imaging marker of amyloid-beta (A ) peptide-related cerebral amyloidosis
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
The in vivo imaging probe [11C]-PIB (Pittsburgh Compound B, N-methyl[11C]2-(4'-methylaminophenyl-6-hydroxybenzathiazole) is under evaluation as a key imaging tool in Alzheimer's disease (AD) and to date has been assumed to bind with high affinity and specificity to the amyloid structures associated with classical plaques (CPs), one of the pathological hallmarks of the disease. However, no studies have systematically investigated PIB binding to human neuropathological brain specimens at the tracer concentrations achieved during in vivo imaging scans. Using a combination of autoradiography and histochemical techniques, we demonstrate that PIB, in addition to binding CPs clearly delineates diffuse plaques and cerebrovascular amyloid angiopathy (CAA). The interaction of PIB with CAA was not fully displaceable and this may be linked to the apolipoprotein E-epsilon4 allele. PIB was also found to label neurofibrillary tangles, although the overall intensity of this binding was markedly lower than that associated with the amyloid-beta (Abeta) pathology. The data provide a molecular explanation for PIB's limited specificity in diagnosing and monitoring disease progression in AD and instead indicate that the ligand is primarily a non-specific marker of Abeta-peptide related cerebral amyloidosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Images of adjacent MFG sections from two Category A pathology cases (A1in A^C ; A2 in D^G ), showing correspondence of [3H]-PIB binding ( A and D ) with 6E10-immunoreactive A b deposits ( C and F ). NDB is demonstrated in sections treated with the non-radioactive competitive ligand BTA-1 ( B and E ). Black arrows demonstrate a number of specific corresponding features. Asterisks mark staining artefacts on 6E10 sections. Higher power representative images of boxed area from case A2 arranged in consecutive cryostat order ( G ). Selected corresponding pathological features are highlighted in pink (DPs), orange (CPs) and blue (CAA). Scale bar 1mm.](https://figures.cochat.ai/paper-figures/53cf42bb40d34aaf9b53cf4f09ffbcbc/pib-is-a-non-specific-imaging-marker-of-amyloid-beta-a-peptide-related-cerebral-figure-1.png)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Pittsburgh Compound B retention is not specific for CAA as opposed to Alzheimer disease, because the compound binds to both vascular and parenchymal amyloid158; however, the 2 pathologies may be distinguishable in part by the relative occipital predominance of labeling in CAA.156,157”
From Vascular Contributions to Cognitive Impairment and Dementia: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association (2011) · cites this paper as [158]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 5×
“…vivo observations with data from both the large number of antecedent postmortem studies detailing the regional, microscopic spread of AD pathology (Braak and Braak, 1991a; Berg et al., 1998; Price and Morris, 1999) and the relatively sparse literature characterizing the interaction of imaging…”
BackgroundMethodInfluentialMirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496 · cited 5×
“Additionally, an inverse correlation of PIB retention with the pattern of decreased regional cerebral glucose metabolism rate (rCMRglc) has been observed (Klunk et al., 2004; Buckner et al., 2005; Engler et al., 2006; Edison et al., 2007).”
BackgroundResultInfluentialConsortium to Establish a Registry for Alzheimer's Disease (CERAD)
Fillenbaum, G. G., & Heyman, A. (2002) · Principles and Practice of Geriatric Psychiatry · doi:10.1002/0470846410.ch42(iii · Cited by 2,410
Buckner, R. L., Snyder, A. Z., Shannon, B. J., LaRossa, G., Sachs, R., Fotenos, A. F., Sheline, Y. I., Klunk, W. E., Mathis, C. A., Morris, J. C., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2177-05.2005 · Cited by 2,140 · cited 3×
“…retention of [11C]-PIB in brain regions not normally associated with a high CP load such as the striatum and frontal cortex (Klunk et al., 2004; Nordberg, 2004; Buckner et al., 2005; Engler et al., 2006; Edison et al., 2007) cannot readily be explained by the reported specificity of PIB for CPs.”
BackgroundInverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans
Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246
Imaging β-amyloid burden in aging and dementia
Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., Cowie, T. F., Dickinson, K. L., Maruff, P., Darby, D., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000261919.22630.ea · Cited by 1,104
[ 11 C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease
Mintun, M. A., LaRossa, G. N., Sheline, Y. I., Dence, C. S., Lee, S. Y., Mach, R. H., Klunk, W. E., Mathis, C. A., DeKosky, S. T., & Morris, J. C. (2006) · Neurology · doi:10.1212/01.wnl.0000228230.26044.a4 · Cited by 1,036
Synthesis and Evaluation of 11C-Labeled 6-Substituted 2-Arylbenzothiazoles as Amyloid Imaging Agents
Mathis, C. A., Wang, Y., Holt, D. P., Huang, G.-F., Debnath, M. L., & Klunk, W. E. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030026b · Cited by 979 · cited 1×
“…protocols used in this study differ significantly from the previous studies investigating the interaction of PIB with human brain sections (Klunk et al., 2003; Mathis et al., 2003, 2004; Bacskai et al., 2007) and that these may explain the novel findings associated with the current study.”
Alzheimer’s amyloid fibrils: structure and assembly
Serpell, L. C. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(00)00029-6 · Cited by 959 · cited 1×
“Both Ab, which forms the fibrils variably associated with SPs (and cerebrovascular amyloid), and tau, which forms the paired helical and straight filaments associated with NFTs, are types of amyloid (Serpell, 2000; Berriman et al., 2003; Barghorn et al., 2004).”
Background
Research works printed but not linked: 3
- Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothia- zoles as amyloid imaging agents. J Med Chem 2003; 46: 2740-54.
- Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006; 67: 446-52.
- Rabinovici GD, Furst AJ, O'Neil JP, et al. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 2007; 68: 1205-12.
Cited by
Items 201–300 of 311
Miki, T., Shimada, H., Kim, J., Yamamoto, Y., Sugino, M., Kowa, H., Heurling, K., Zanette, M., Sherwin, P. F., & Senda, M. (2017) · Annals of Nuclear Medicine · doi:10.1007/s12149-017-1154-7 · Cited by 17
Tsai, H.-H. C., Pasi, M., Liu, C., Tsai, Y.-C., Yen, R., Chen, Y., Jeng, J., Tsai, L., Charidimou, A., & Baron, J. (2025) · Journal of Stroke · doi:10.5853/jos.2024.02376 · Cited by 14
Article Commentary: Alzheimer's Disease, Diagnosis and the Need for Biomarkers
Hooper, C., Lovestone, S., & Sáinz‐Fuertes, R. (2008) · Biomarker Insights · doi:10.4137/bmi.s682 · Cited by 14
“Interestingly, PiB has also been shown to bind to NFTs as well as Aβ (Lockhart et al. 2007), thus, in the future perhaps enabling clinicians to perform virtual brain biopsies (Agronin, 2008).”
Geriatric Medicine, Japanese Alzheimer's Disease Neuroimaging Initiative and Biomarker Development
Arai, H., Okamura, N., Furukawa, K., & Kudo, Y. (2010) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.221.87 · Cited by 14
“An autoradiographic study using AD brain sections revealed that [(11)C]PIB, in addition to binding to the classical fibrillar Aβ plaques, also binds to a range of Aβ containing lesions including diffuse plaques and cerebrovascular amyloid angiopathy (Lockhart et al. 2007).”
BackgroundSheikh‐Bahaei, N., Manavaki, R., Sajjadi, S. A., Priest, A. N., O'Brien, J. T., & Gillard, J. H. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180443 · Cited by 13
[18F]FDG PET may differentiate cerebral amyloid angiopathy from Alzheimer’s disease
Bergeret, S., Queneau, M., Rodallec, M. H., Curis, E., Dumurgier, J., Hugon, J., Paquet, C., Farid, K., & Baron, J. (2021) · European Journal of Neurology · doi:10.1111/ene.14743 · Cited by 13
“[15] Although initially developed for the early detection of tissular amyloid plaques, amyloid radiotracers also bind to vascular amyloid in vitro.[16] They thus hold diagnostic potential in CAA too.”
BackgroundChang, Y. Z., Liu, J., Wang, L. Y., Li, X., Wang, Z., Lin, M., Jin, W., Zhu, M., & Xu, B. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.721780 · Cited by 15
Song, J., Peng, X., Li, L., Yang, F., Zhang, X., Zhang, J., Dai, J., & Cui, M. (2018) · ACS Omega · doi:10.1021/acsomega.8b01120 · Cited by 13
Mapping the binding site topology of amyloid protein aggregates using multivalent ligands
Sanna, E., Rodrigues, M., Fagan, S. G., Chisholm, T. S., Kulenkampff, K., Klenerman, D., Spillantini, M. G., Aigbirhio, F. I., & Hunter, C. A. (2021) · Chemical Science · doi:10.1039/d1sc01263k · Cited by 12
Arbizu, J., García‐Ribas, G., Carrió, I., Garrastachu, P., Martínez‐Lage, P., & Molinuevo, J. L. (2015) · Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) · doi:10.1016/j.remnie.2015.05.004 · Cited by 22
Bartels, A. L., Kortekaas, R., & Leenders, K. L. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2008.04.140 · Cited by 11
The role of Apolipoprotein E4 on cognitive impairment in Parkinson’s disease and Parkinsonisms
Rosal, A. E., Martin, S. L., & Strafella, A. P. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1515374 · Cited by 11
“This is further supported with evidence showing that PiB can bind to Lewy bodies and neurofibrillary tangles in vivo (Fodero-Tavoletti et al., 2007; Lockhart et al., 2007).”
Monitoring the amyloid beta-peptide in vivo – caveat emptor
Thompson, P. W., & Lockhart, A. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2008.12.004 · Cited by 12
Self-citationCerebrospinal Fluid BACE1 Activity and Brain Amyloid Load in Alzheimer's Disease
Grimmer, T., Alexopoulos, P., Tsolakidou, A. F., Guo, L., Henriksen, G., Yousefi, B. H., Förstl, H., Sorg, C., Kurz, A., Drzezga, A. E., et al. (2012) · The Scientific World JOURNAL · doi:10.1100/2012/712048 · Cited by 12
Raval, N. R., Nasser, A., Madsen, C. A., Beschörner, N., Beaman, E. E., Juhl, M., Lehel, S., Palner, M., Svarer, C., Plavén‐Sigray, P., et al. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.847074 · Cited by 9
Waldron, A., Verhaeghe, J. A. J., Wyffels, L., Schmidt, M. E., Langlois, X., der Linden, A. V., Stroobants, S. G., & Staelens, S. G. (2015) · Molecular Imaging and Biology · doi:10.1007/s11307-015-0833-9 · Cited by 12
Biomarkers for Alzheimer’s Disease
Farooqui, A. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809937-7.00007-0 · Cited by 9
The Value of In Vitro Binding as Predictor of In Vivo Results: A Case for [18F]FDDNP PET
Cole, G. B., Satyamurthy, N., Liu, J., Wong, K. P., Small, G. W., Huang, S., Košmrlj, J., Barrio, J. R., & Petrič, A. (2018) · Molecular Imaging and Biology · doi:10.1007/s11307-018-1210-2 · Cited by 8
Identification of Multicolor Fluorescent Probes for Heterogeneous Aβ Deposits in Alzheimer’s Disease
Mukherjee, A., Al‐Lahham, R., Corkins, M. E., Samanta, S., Schmeichel, A. M., Singer, W., Low, P. A., Govindaraju, T., & Soto, C. A. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.802614 · Cited by 8
“In fact, the most well-established diagnostic probe targeted toward Aβ aggregates, the Pittsburgh compound B (PiB), which is a derivative of Thioflavin, can also bind a subset of tau aggregates present in the AD brain (Lockhart et al., 2007; Ikonomovic et al., 2008).”
BackgroundJia, J., Sun, B., Guo, Z., Zhang, J., Tian, J., Tang, H., & Wang, L. (2010) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-010-9111-2 · Cited by 8
Cohen, A. D., & Villemagne, V. L. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70291 · Cited by 7
“85,88 This is important as AD is described as a “triple brain amyloidosis.””
InfluentialRay, S., Kumar, M., Chemparathy, D. T., Dash, P. K., & Sil, S. (2025) · Journal of Extracellular Vesicles · doi:10.1002/jev2.70191 · Cited by 7
When Does Alzheimer’s Disease Really Start? The Role of Biomarkers
Lloret, A., Esteve, D., Lloret, M.-Á., Cervera‐Ferri, A., Lopez, B., Nepomuceno, M., & Monllor, P. (2021) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.19305 · Cited by 8
Michiels, L., Dobbels, L., Demeestere, J., Demaerel, P., Laere, K. V., & Lemmens, R. (2022) · NeuroImage Clinical · doi:10.1016/j.nicl.2022.103107 · Cited by 7
Mechanisms underlying microbleeds
Werring, D. J. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511974892.009 · Cited by 7
Measuring disease progression in corticobasal syndrome
Huang, N., Hornberger, M., Hodges, J. R., & Burrell, J. R. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7389-5 · Cited by 7
Shokouhi, S., Campbell, D. L., Brill, A. B., Gwirtsman, H. E., & Initiative, T. A. D. N. (2016) · Brain Pathology · doi:10.1111/bpa.12399 · Cited by 7
Positron Emission Tomography in Alzheimer Disease
Schmidt, M. E., Matthews, D. C., Andrews, R. D., & Mosconi, L. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-386945-6.00005-6 · Cited by 7
Les marqueurs de la maladie d’Alzheimer prodromale
de Souza, L. C., Sarazin, M., Uspenskaya, O., Habert, M., Lamari, F., Lehéricy, S., & Dubois, B. (2012) · Revue Neurologique · doi:10.1016/j.neurol.2012.07.005 · Cited by 6
Hunter, S., & Brayne, C. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.015 · Cited by 7
Pivtoraiko, V. N., Racic, T., Abrahamson, E. E., Villemagne, V. L., Handen, B. L., Lott, I. T., Head, E., & Ikonomović, M. D. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.728739 · Cited by 7
Promteangtrong, C., Kolber, M., Ramchandra, P., Moghbel, M. C., Houshmand, S., Schöll, M., Werner, T. J., Alavi, A. A., & Buchpiguel, C. A. (2015) · Dementia & Neuropsychologia · doi:10.1590/1980-57642015dn94000330 · Cited by 7
Bousser, M., & Chabriat, H. (2012) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)31836-9 · Cited by 7
Grimmer, T., Drzezga, A. E., & Kurz, A. (2010) · Der Nervenarzt · doi:10.1007/s00115-010-2951-6 · Cited by 7
Evaluation of Early Dementia (Mild Cognitive Impairment)
Osorio, R. S., Berti, V., Mosconi, L., Li, Y., Glodzik, L., Santi, S. D., & de Leon, M. J. (2010) · PET Clinics · doi:10.1016/j.cpet.2009.12.003 · Cited by 5
Neuroimaging of Alzheimer’s Disease, Mild Cognitive Impairment, and Other Dementias
Risacher, S. L., & Saykin, A. J. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6373-4_19 · Cited by 5
Imaging biomarkers for amyloid: a new generation of probes and what lies ahead
Leuzy, A., Zimmer, E. R., Bhat, V., Rosa‐Neto, P., & Gauthier, S. G. (2014) · International Psychogeriatrics · doi:10.1017/s1041610214000118 · Cited by 4
Aβ Imaging in Aging, Alzheimer’s Disease and Other Neurodegenerative Conditions
Villemagne, V. L., Fodero‐Tavoletti, M. T., Yates, P. A., Masters, C. L., & Rowe, C. C. (2014) · Springer eBooks · doi:10.1007/978-3-642-54307-4_10 · Cited by 4
PET and SPECT Imaging of Neurodegenerative Diseases
Drzezga, A. E., Bischof, G. N., Giehl, K., & van Eimeren, T. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-816386-3.00085-5 · Cited by 4
Advances in Retinal Imaging: Retinal Amyloid Imaging
Koronyo‐Hamaoui, M., Doustar, J., Oviatt, M., Black, K. L., & Koronyo, Y. (2020) · Springer eBooks · doi:10.1007/978-3-030-26269-3_6 · Cited by 5
Amyloid Imaging in Dementia and Neurodegenerative Disease
Ponisio, M. R., Iranpour, P., & Benzinger, T. L. S. (2021) · Springer eBooks · doi:10.1007/978-3-030-82367-2_11 · Cited by 4
Beyond PIB: the next generation of amyloid‐imaging ligands
Shinotoh, H., & Suhara, T. (2008) · Psychogeriatrics · doi:10.1111/j.1479-8301.2008.00246.x · Cited by 4
Cerebellar Microbleed Patterns: Potential Relevance for the Boston Criteria, Version 2.0
Smith, E. E., & Wollenweber, F. A. (2019) · Stroke · doi:10.1161/strokeaha.119.027416 · Cited by 4
A Review of Functional Neuroimaging in People with Down Syndrome with and without Dementia
Deinde, F., Kotecha, J., Lau, L. S. L., Bhattacharyya, S., & Velayudhan, L. (2021) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000520880 · Cited by 3
Goyzueta-Mamani, L. D., Chávez‐Fumagalli, M. Á., Alvarez, K. L. F., Aguilar-Pineda, J. A., Nieto-Montesinos, R., Dávila-Del-Carpio, G., Vera-López, K. J., & Cardenas, C. L. L. (2022) · Recent Patents on Biotechnology · doi:10.2174/1872208316666220408114129 · Cited by 3
SPECT/PET Findings in Lewy Body Dementia
Ducksbury, R., Whitfield, T. J., & Walker, Z. (2014) · Springer eBooks · doi:10.1007/978-3-642-54307-4_17 · Cited by 4
Synthesis optimization of pittsburgh compound B by the captive solvent method
Clemente, G. S., Alves, V., & Abrunhosa, A. (2012) · IEEE Portuguese Meeting on Bioengineering · doi:10.1109/enbeng.2012.6331358 · Cited by 4
Neuropathology of HIV-1 Disease
Soontornniyomkij, V. (2017) · Springer eBooks · doi:10.1007/978-1-4939-7290-6_8 · Cited by 4
Prion-Like Propagation in Neurodegenerative Diseases
Peelaerts, W., Baekelandt, V., & Brundin, P. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811304-2.00008-0 · Cited by 4
SPECT/PET Findings in Dementia with Lewy Bodies
Zabihi, S., Whitfield, T. J., & Walker, Z. (2020) · Springer eBooks · doi:10.1007/978-3-030-53168-3_17 · Cited by 3
Advances in Imaging: Brain Tumors to Alzheimer’s Disease
Patil, R., Koronyo, Y., Ljubimov, A. V., Salumbides, B. C., Mamelak, A. N., Gangalum, P. R., Ding, H., Portilla‐Arias, J., Holler, E., Butte, P. V., et al. (2015) · THE BANGKOK MEDICAL JOURNAL · doi:10.31524/bkkmedj.2015.09.017 · Cited by 2
Aβ Imaging in Aging, Alzheimer’s Disease, and Other Neurodegenerative Conditions
Villemagne, V. L., Doré, V., Burnham, S. C., & Rowe, C. C. (2020) · Springer eBooks · doi:10.1007/978-3-030-53168-3_10 · Cited by 2
Diagnosis of Dementia Using Nuclear Medicine Imaging Modalities
Merissa, N., Garrett, M., & Scott, P. J. H. (2011) · InTech eBooks · doi:10.5772/25283 · Cited by 3
Kepe, V. (2013) · PET Clinics · doi:10.1016/j.cpet.2013.08.002 · Cited by 2
Amyloid imaging in Alzheimer’s disease: a potential new era of personalized medicine?
Leuzy, A., Zimmer, E. R., Gauthier, S. G., & Rosa‐Neto, P. (2014) · Translational Neuroscience · doi:10.2478/s13380-014-0205-y · Cited by 3
Amyloid imaging for Alzheimer's disease
Kerchner, G. A. (2011) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530059.2011.617365 · Cited by 2
Relationship of cerebral microbleeds to other imaging findings
Smith, E. E., Werring, D. J., & McCreary, C. R. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511974892.011 · Cited by 2
Müller, M. L. T. M., & Bohnen, N. I. (2018) · Contemporary clinical neuroscience · doi:10.1007/978-3-319-78926-2_7 · Cited by 2
Le diagnostic de la maladie d’Alzheimer : l’apport de la recherche préclinique
Delatour, B., & Dhénain, M. (2008) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)32835-3 · Cited by 2
Structural and Molecular Imaging of Aging Brain
Ghonim, M., Ghonim, M., Redden, H. W. K., Gharavi, D., Mamidi, R. S., Patel, D., Mirbod, M., Revheim, M.-E. R., Werner, T. J., Newberg, A. B., et al. (2024) · PET Clinics · doi:10.1016/j.cpet.2024.09.007 · Cited by 1
Liu, H., Li, S., Li, X., Li, S., Wu, J., Chen, D., & Xia, C. (2025) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2025.126582 · Cited by 1
Role of Nanotechnology in the Diagnosis and Treatment of Alzheimer’s Disease
Jaruszewski, K. M., Omtri, R. S., & Kandimalla, K. K. (2012) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/978160805131111201010107 · Cited by 2
Closing the gap between research techniques and clinical practice in the treatment of dementia
Wicklund, A. H., & Gaviria, M. (2011) · Surgical Neurology International · doi:10.4103/2152-7806.90030 · Cited by 1
“the spectrum from normal aging to a clinical diagnosis of AD dementia.[9,13,16] The value of these techniques in diagnosis and early intervention is being examined.”
BackgroundJahng, G., Xu, S., & Kim, M. (2012) · Medical Physics · doi:10.1118/1.4754655 · Cited by 1
Biomarkers for Alzheimer's Dementia : Focus on Neuroimaging
Won, W. Y., & Lee, C. U. (2011) · Saengmul jeongsin euihag/Saengmul jeongsin uihak · Cited by 2
Lamar, M., Wortzel, H. S., Libon, D. J., Wambach, D. M., Price, C. C., & Kumar, A. A. (2012) · Wiley eBooks · doi:10.1002/9781119968900.ch4 · Cited by 1
Molecular imaging evidence in favor or against PDD and DLB overlap
Caminiti, S. P., & Carli, G. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821651-4.00015-4 · Cited by 3
Biomarkers and Alzheimer spectrum
Takeda, M. (2011) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2011.02197.x · Cited by 1
“In recent years, several ligands specific to amyloid beta peptide (Ab) have been developed, which reflect the level of Ab accumulation in the brain.(26) (11)Clabeled ligand, Pittsburg compound B ((11)C-PIB) specifically binds to amyloid deposition in senile plaques, diffuse plaques and amyloid angiopathy in the affect…”
BackgroundL’imagerie moléculaire de la démence : quels moyens pour répondre à quelles questions ?
Goldman, S. (2008) · Médecine Nucléaire · doi:10.1016/j.mednuc.2008.05.002 · Cited by 1
Positron Emission Tomography in Alzheimer‘s Disease: Early Prediction and Differentiation
Mistur, R. L., Mosconi, L., Santi, S. D., Li, Y., Tsui, W., & de Leon, M. J. (2008) · Future Neurology · doi:10.2217/14796708.4.1.23 · Cited by 1
Kalemis, A., Binnie, D. M., Flower, M. A., & Ott, R. J. (2009) · Medical Image Analysis · doi:10.1016/j.media.2009.08.002 · Cited by 1
11 The Early Detection of Alzheimer's Disease with Positron Emission Tomography
Mistur, R. L., Mosconi, L., Switalski, R., Santi, S. D., Li, Y., Glodzik, L., Bryś, M., Tsui, W., Rusinek, H., & de Leon, M. J. (2009) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195328875.003.0011 · Cited by 1
Zaidi, H., & Alavi, A. A. (2007) · PET Clinics · doi:10.1016/j.cpet.2007.12.003 · Cited by 1
Drzezga, A. E., & Perneczky, R. (2010) · The Open Nuclear Medicine Journal · doi:10.2174/1876388x01002010053
“While being specific for amyloid pathology in general, [11C]PIB apparently binds to different variants of amyloid-aggregation pathology and, thus, neither allows for a differentiation between different types of plaques nor between plaques and cerebral amyloid angiopathy [13].”
BackgroundAmyloidplaque-Bildgebung in der Demenzdiagnostik
Drzezga, A. E. (2009) · Der Nuklearmediziner · doi:10.1055/s-0028-1128137
Diagnosticare la malattia di Alzheimer
Sarazin, M., Hamelin, L., Lamari, F., & Bottlaender, M. (2014) · EMC - Neurologia · doi:10.1016/s1634-7072(14)67223-8
Onami, S. H. (2010) · Berkeley Scientific Journal · doi:10.5070/bs3132007631
Klinischer Nutzen nuklearmedizinischer Verfahren in der Demenzdiagnostik
Drzezga, A. E. (2009) · Nervenheilkunde · doi:10.1055/s-0038-1627142
Grachev, I. D. (2015) · Journal of Neurology & Stroke · doi:10.15406/jnsk.2015.02.00050
Molecular PET imaging for in vivo detection of amyloid in the human brain
Okamura, N. (2009) · Rinsho Shinkeigaku · doi:10.5692/clinicalneurol.49.922
Targeting Tau Aggregation for the Diagnosis and Treatment of Alzheimer's Disease
Schafer, N. D. (2013) · OhioLink ETD Center (Ohio Library and Information Network)
The Current Status of Alzheimer's Disease Treatment
Lanctôt, K. L., Kircanski, I., Chau, S. A., & Herrmann, N. (2012) · Frontiers in neuroscience · doi:10.1201/b11986-5 · Cited by 1
Drzezga, A. E. (2016) · Springer eBooks · doi:10.1007/978-3-319-30081-8_26 · Cited by 1
The lived experience of dementia
Nurock, S. (2017) · doi:10.1201/9781315381572-11
Jeppsson, F. (2016) · DiVA (Stockholm University)
Diagnostiquer la maladie d'Alzheimer
Sarazin, M., Hamelin, L., Lamari, F., & Bottlaender, M. (2013)
Klein, E. (2017) · Open Archive Toulouse Archive Ouverte (University of Toulouse) · Cited by 1
Modak, S. (2013) · Research Explorer (The University of Manchester)
Detection of amyloid aggregation in living systems
Broersen, K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819132-3.00007-5
Les amyloïdoses : détection à l'aide de nanoparticules et propriétés optiques originales
Pansieri, J. (2017) · theses.fr (ABES) · doi:10.70675/0e785fbcz0be7z4c5fz8158zc5e08a3c8269 · Cited by 1
Lindgrén, N. (2021) · UTUPub (University of Turku) · Cited by 2
(2008) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32831cbb85
Saint‐Aubert, L. (2012) · Thèses en ligne de l'Université Toulouse III (Université Toulouse III)
Faculty Opinions recommendation of Imaging amyloid deposition in Lewy body diseases.
Stacy, M. A. (2008) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.1125917.583025
Waldron, A., Verhaeghe, J. A. J., Wyffels, L., Schmidt, M. E., Langlois, X., der Linden, A. V., Stroobants, S. G., & Staelens, S. G. (2015) · Molecular Imaging and Biology · doi:10.1007/s11307-015-0905-x
Metadata
- Authors
- Lockhart, A., Lamb, J. R., Osredkar, T., Sue, L. I., Joyce, J. N., Ye, L., Libri, V., Leppert, D., & Beach, T. G.
- Affiliations
- GlaxoSmithKline (United Kingdom) (GB)
- University Hospital of Basel (CH)
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-10-01
- Volume
- 130
- Issue
- 10
- Pages
- 2607-2615
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2031309116
- Cited by
- 302
- References
- 55
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 2 · 2023: 3 · 2022: 8 · 2021: 15 · 2020: 11 · 2019: 9 · 2018: 9 · 2017: 13 · 2016: 15 · 2015: 18 · 2014: 17 · 2013: 25 · 2012: 35
- FWCI
- 18.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Brain (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Michael J. Fox Foundation for Parkinson's Research (211002, P30 AG19610)
- GlaxoSmithKline
- Arizona Department of Health Services (P30 AG19610, 211002, Contract 211002)
- Arizona Biomedical Research Commission (P30 AG19610, contract 0011, 211002)
- National Institute on Aging (211002, P30-AG-19610, AG-19610, P30AG019610)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Intracerebral and Subarachnoid Hemorrhage Research
- Keywords
- Pittsburgh compound B, [11C]PIB, amyloid-beta, cerebral amyloidosis, Alzheimer's disease, diffuse plaques, neurofibrillary tangles, APOE ε4, autoradiography, amyloid imaging
- MeSH terms
- Alzheimer Disease, Aniline Compounds, Brain, Carbon Radioisotopes, Humans, Thiazoles, Biomarkers, Amyloid beta-Peptides, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.